We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 4 juni 2018

The Lancet: [News] Chlamydia infection and ovarian cancer risk

[News] Chlamydia infection and ovarian cancer risk
According to new research, women with antibodies against Pgp3—a highly accurate serological marker for previous or current Chlamydia trachomatis infection—are twice as likely to develop ovarian cancer, but other markers of infection did not show this association.
Read more

[News] Lung cancer incidence higher in US women than men
There is now a higher incidence of lung cancer in young women than young men in the USA, suggesting a reversal of historical incidence patterns, according to a recent report.
Read more

[Articles] Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib. These results indicate that pembrolizumab might be a treatment option for these patients. This drug is undergoing further assessment in two phase 3, randomised trials as a second-line treatment in patients with hepatocellular carcinoma.
Read more

[Comment] Shaping the landscape of immune oncology in hepatocellular carcinoma
Immune-based strategies have been tested for the treatment of hepatocellular carcinoma since the early 1990s and have yielded unsatisfactory results. However, with the advent of immune checkpoint inhibitors in 2013, which were announced as a major breakthrough in oncology,1 there was a renewed interest in immunotherapy as a potential therapeutic option for cancers that are difficult to treat, such as hepatocellular carcinoma.
Read more

[Articles] Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer compared with abiraterone alone. More serious adverse events were observed in patients who received olaparib and abiraterone than abiraterone alone. Our data suggest that the combination of olaparib and abiraterone might provide an additional clinical benefit to a broad population of patients with metastatic castration-resistant prostate cancer.
Read more